Table 2.
Characteristics of patients grouped by HCV status and Ishak fibrosis stage
| HCV RNA |
HCV Ishak Fibrosis |
|||
|---|---|---|---|---|
| Negative (resolved) | Positive (chronic) | Mild (0−3) | Severe (4−6) | |
| n = 107 | n = 267 | n = 160 | n = 92 | |
| Gender | ||||
| Male | 67 (63%) | 183 (69%)a | 111 (69%) | 63 (69%)a |
| Female | 38 (35%) | 81 (30%) | 49 (31%) | 26 (28%) |
| Unknown | 2 (2%) | 3 (1%) | 0 (0%) | 3 (3%) |
| Risk factor | ||||
| Injecting drug user | 40 (37%) | 151 (56%) | 106 (66%) | 36 (39%) |
| Blood product transfusion | 4 (4%) | 45 (17%) | 27 (17%) | 15 (16%) |
| Other known risk factor | 4 (4%) | 15 (6%) | 6 (4%) | 9 (10%) |
| No known risk factor | 1 (1%) | 33 (12%) | 14 (9%) | 17 (19%) |
| No risk factor data | 58 (54%)b | 23 (9%) | 7 (4%) | 15 (16%) |
| Mean (SD) age at Biopsy (year) | 39 (10) | 50 (11)c | ||
| Mean (SD) duration of Infection (year) | 17 (8) | 23 (10)c | ||
| Median weekly alcohol intake (range) | 4 (0−65) | 0 (0−60)d | ||
a
NS (χ 2 test);
b
Risk factor data was not routinely collected from HCV RNA negative patients;
c
p < 0.001 (unpaired t‐test);
d
p = 0.001 (Mann−Whitney U test).